[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracranial-aneurysms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracranial-aneurysms":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,72,94,129,171,196,217,237],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644750","surface-modified-flow-diverter-for-intracranial-aneurysms-assessment-of-ischemic-and-clinical-outcomes-100644750",false,"NCT07674004","Surface-Modified Flow Diverter for Intracranial Aneurysms: Assessment of Ischemic and Clinical Outcomes","Prospective Randomized Controlled Trial of Surface-Modified Flow Diverter for Intracranial Aneurysms: Multicenter Assessment of Ischemic and Clinical Outcomes","PRISMATIC","Inclusion Criteria:\n\n1. Patients were diagnosed with unruptured intracranial aneurysms, and the lesions were evaluated to be suitable for endovascular treatment with flow diverter devices (PED Shield\u002FLattice).\n2. During the study period, only one target aneurysm per patient was treated, with the exception of segmental lesions, in which multiple aneurysms located within the same arterial segment were treated with a single or overlapping study devices.\n3. The target aneurysm was treated solely with flow diverter (FD) implantation in the current study.\n4. The age of enrolled patients ranged from 18 to 75 years old.\n5. Patients were capable of understanding the study-related informed consent information and provided written informed consent for the use of their clinical data for research purposes.\n\nExclusion Criteria:\n\n1. Patients with a prior history of endovascular treatment for the target aneurysm.\n2. Patients in the acute stage of cerebrovascular diseases (acute cerebral infarction or intracerebral hemorrhage with an onset time of ≤ 2 weeks).\n3. Patients complicated with other cerebrovascular disorders, including moyamoya disease, cerebrovascular malformations, and arteriovenous fistula.\n4. Patients with atherosclerotic changes in the parent artery of the target aneurysm that necessitated additional intraoperative endovascular interventions (e.g., balloon angioplasty or conventional stent implantation).\n5. Patients with a preoperative modified Rankin Scale (mRS) score greater than 2.\n6. Patients with any absolute contraindications to device treatment as specified in the Instructions for Use (IFU).\n7. Patients enrolled in other clinical trials that may interfere with the primary or secondary endpoints of the present study.\n8. Patients with comorbidities that may interfere with neurological function evaluation, affect survival status, or impair the ability to complete follow-up visits.\n9. Pregnant or lactating female patients.","ALL","18 Years","75 Years",{"count":21,"type":22},196,"ESTIMATED","INTERVENTIONAL",[25],"NA","Flow diverters (FDs) have become a mainstay of endovascular therapy for unruptured intracranial aneurysms (UIAs), yet their implantation carries an inherent risk of ischemic complications. The Pipeline Flex Embolization Device with Shield Technology (PED Shield) and the Lattice Flow Diverter (LFD) are two surface-modified FDs that have shown promising efficacy for mitigating procedure-related ischemic events in prior single-arm or retrospective series. Nevertheless, head-to-head comparative data between these two surface-modified flow diverters remain scarce, and prospective randomized clinical trials are warranted to corroborate their differential performance in lowering ischemic complication risks.This prospective, multicenter randomized controlled trial (RCT) was designed to compare the efficacy of PED Shield versus LFD in reducing ischemic complications after endovascular treatment of UIAs. A total of 196 eligible participants who meet the predefined inclusion and exclusion criteria will be enrolled in the trial. The primary outcome measure is the incidence of new diffusion-weighted imaging (DWI)-positive lesions on brain magnetic resonance imaging (MRI) within 48 hours after the procedure. The secondary outcome measures consist of perioperative symptomatic ischemic events, all-cause mortality and disability rate during the follow-up period, delayed aneurysm rupture at the 6-month follow-up, complete aneurysm occlusion rate, incidence of major in-stent stenosis (stenosis degree \\>50%) at the 6-month follow-up, and the number of new DWI-positive lesions within 48 hours post-procedure.",[28,29],"Intracranial Aneurysms","Flow Diverter",[31,32,33],"intracranial aneurysms","flow dierters","surface-modified","RECRUITING","2026-06-29",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":40,"type":38},"2026-05-21",{"date":42,"type":22},"2027-09-30",{"name":44,"class":45},"Henan Provincial People's Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100638075","prospective-study-of-high-penetration-super-resolution-transcranial-ultrasound-for-early-identification-of-postoperative-intracranial-metallic-targets-after-aneurysm-clipping-100638075","NCT07583225","Prospective Study of High-penetration Super-resolution Transcranial Ultrasound for Early Identification of Postoperative Intracranial Metallic Targets After Aneurysm Clipping","Clinical Model-Based Evaluation of High-Penetration Super-Resolution Transcranial Ultrasound for Early Diagnosis of Intracranial Metallic Foreign Bodies in Patients After Intracranial Aneurysm Clipping","HPSR-TCUS Clip","Inclusion Criteria:\n\n1. Age 18-85 years;\n2. Positive group: patients undergoing intracranial aneurysm clipping with implanted metallic clips; negative control group: postoperative craniotomy patients without implanted clips;\n3. Ability to complete transcranial ultrasound within 3 hours after surgery;\n4. Availability of postoperative CT;\n5. Written informed consent from the participant or legally authorized representative.\n\nExclusion Criteria:\n\n1. Inability to complete standardized transcranial ultrasound;\n2. Missing postoperative CT;\n3. Inability to establish the composite reference standard;\n4. Presence of non-study-related metallic materials that may substantially interfere with target identification;\n5. Withdrawal of consent;\n6. Investigator judgment that continued participation is inappropriate.","85 Years",{"count":57,"type":22},78,"1 Day","OBSERVATIONAL","To evaluate the patient-level early diagnostic performance of high-penetration super-resolution transcranial ultrasound for identifying intracranial metallic targets, and to further assess clip-level detection, localization, agreement, and its complementary value to routine postoperative imaging.This study does not alter routine clinical treatment. All participants will undergo standardized high-penetration super-resolution transcranial ultrasound within 3 hours after surgery. Postoperative CT is mandatory for all participants; CTA or other routine postoperative imaging will be obtained only when clinically indicated.",[28],"NOT_YET_RECRUITING","2026-05-12",{"date":65,"type":38},"2026-05-15",{"date":67,"type":22},"2026-05-30",{"date":69,"type":22},"2027-04-30",{"name":71,"class":45},"Chinese PLA General Hospital",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100636736","clinical-organizational-and-care-impact-of-the-getready-digital-platform-as-a-clinical-decision-support-tool-in-the-follow-up-of-patients-with-cerebral-aneurysm-100636736","NCT07569562","Clinical, Organizational, and Care Impact of the GetReady Digital Platform as a Clinical Decision Support Tool in the Follow-up of Patients With Cerebral Aneurysm","Smart Aneurysm FOllow-up","SAFO","Inclusion Criteria:\n\n* Diagnosis of cerebral aneurysm\n* Access to one of the following: compatible mobile phone, computer, or tablet with internet access\n* Sufficient internet connection for use of the digital platform\n* When the patient cannot or does not wish to use the application directly, participation may occur through a designated caregiver or family member, after informed consent\n\nExclusion Criteria:\n\n* Patients treated with surgical clipping\n* Absence of informed consent",{"count":81,"type":22},200,[25],"This study evaluates the clinical, organizational, and care impact of the GetReady digital platform as a clinical decision support tool for the follow-up of patients with cerebral aneurysm. The platform integrates clinical, radiological, and patient-reported data, including PROMs and PREMs, and may incorporate home blood pressure monitoring. The study is an interventional implementation study with retrospective and prospective components. No additional medical, diagnostic, or therapeutic intervention is introduced, and all clinical decisions remain under routine clinical practice.",[28],"2026-04-29",{"date":87,"type":38},"2026-05-06",{"date":89,"type":22},"2026-05-18",{"date":91,"type":22},"2028-12-31",{"name":93,"class":45},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":113,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":46},"100611866","non-invasive-blood-pressure-monitoring-in-intracranial-aneurysm-embolization-100611866","NCT07246148","NOn-inVAsive Blood Pressure Monitoring in Intracranial Aneurysm Embolization","A Randomized Controlled Trial on Non-Invasive Continuous Blood Pressure Monitoring as an Alternative to Radial Arterial Catheterization in Patients Undergoing Coil Embolization for Intracranial Aneurysms","NOVA","Inclusion Criteria:\n\n* Adult patients (≥19 and ≤80 years old) scheduled for elective coil embolization of unruptured intracranial aneurysms under general anesthesia.\n* American Society of Anesthesiologists (ASA) physical status classification I-III.\n\nExclusion Criteria:\n\n* Patients who do not provide informed consent.\n* Patients unable to understand or follow study instructions due to physical or mental limitations.\n* Patients in whom radial arterial catheterization is not feasible (e.g., peripheral vascular disease, skin disorders at the insertion site, absence of radial\u002Fulnar artery, or orthopedic conditions of the upper extremity).\n* Patients with peripheral vascular circulatory disorders.\n* Patients with morbid obesity (BMI ≥ 40 kg\u002Fm²) \\[Eley et al., 2021\\].\n* Patients who are hemodynamically unstable preoperatively or expected to be unstable during the perioperative period.","19 Years","80 Years",{"count":105,"type":22},50,[25],"The goal of this clinical trial is to evaluate whether non-invasive continuous blood pressure monitoring (NVBP) using the ClearSight system can safely serve as an alternative to radial arterial catheterization for invasive arterial blood pressure monitoring (IABP) in patients undergoing coil embolization for unruptured intracranial aneurysms.\n\nThe main questions it aims to answer are:\n\n* Does NVBP monitoring detect intraoperative hypotension and hypertension events with similar reliability compared to IABP?\n* Does NVBP monitoring reduce the need for invasive arterial catheterization without compromising patient safety or clinical outcomes?\n\nResearchers will compare patients assigned to NVBP monitoring with those receiving conventional IABP monitoring.\n\nParticipants will:\n\n* Be randomly assigned to NVBP monitoring or standard IABP monitoring during coil embolization.\n* Receive continuous monitoring of cerebral oxygenation with near-infrared spectroscopy (rSO₂).\n* Undergo standard anesthesia induction, maintenance, and postoperative intensive care protocols.\n* Have their intraoperative hemodynamic events, vasopressor use, and postoperative outcomes recorded up to 30 days after the procedure.",[109,28,110,111,112],"Cerebral Aneurysms","Coil Embolization","Hemodynamic Instability","Noninvasive Cardiac Monitoring",[114,115,116,117,118,119],"non-invasive blood pressure monitoring","continuous arterial blood pressure monitoring","coil embolization","neuroanesthesia","cerebral oximetry","radial arterial catheterization","2026-04-06",{"date":122,"type":38},"2026-04-09",{"date":124,"type":38},"2026-01-01",{"date":126,"type":22},"2027-08-31",{"name":128,"class":45},"Korea University Anam Hospital",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":137,"targetDuration":139,"studyType":59,"phases":4,"briefSummary":140,"conditions":141,"keywords":150,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":170},"100629458","targeting-real-world-usage-in-stroke-treatment-100629458","NCT07474935","Targeting Real World Usage In Stroke Treatment","TRUST Registry - Targeting Real World Usage In Stroke Treatment A WallabyPhenox Hemorrhagic Stroke Registry","TRUST","Inclusion Criteria:\n\n* Subject treated or intended to be treated with at least one target registry device during the procedure (i.e., at least one attempt of introduction into the vasculature of the subject),\n* Non-opposition to data collection or informed consent provided by the subject or legal representative as per country-specific legislation.\n\nExclusion Criteria:\n\n* Participation in an interventional study modifying standard care management for all relevant indications,",{"count":138,"type":22},5000,"5 Years","TRUST Registry is an observational, prospective, long-term, post-market surveillance registry of subjects treated with WallabyPhenox flow modulation devices, stent systems, bifurcation aneurysm implants including their HPC variants (Hydrophilic Polymer Coating) where applicable as well as coil systems, and other adjunctive medical devices.\n\nThe overarching purpose of this registry is to carry out a proactive gathering, recording, and analysis of data on the safety, performance and usability of the devices as applied within the routine practice of the participating registry sites.",[142,143,144,145,146,147,148,149,28],"Saccular and Fusiform Aneurysms","Pseudoaneurysm","Vascular Dissection","Perforation","Bifurcation Aneurysms","Stenosis","Neurovascular Abnormalties","Wide-neck Aneurysm",[151,152,29,153,154,155,156,157,158,159],"TRUST Registry","Registry study","WallabyPhenox","p48 MW (HPC)","p64","Avenir Coil","p64 MW (HPC)","pEGASUS HPC","pCONUS 2 (HPC)","2026-03-11",{"date":162,"type":38},"2026-03-16",{"date":164,"type":38},"2026-01-29",{"date":166,"type":22},"2041-01",{"name":168,"class":169},"Phenox GmbH","INDUSTRY",13,{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":179,"targetDuration":181,"studyType":59,"phases":4,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":46},"100628684","pc400-coils-for-treatment-of-intracranial-aneurysms-100628684","NCT07464847","PC400 Coils for Treatment of Intracranial Aneurysms","Penumbra PC400 Coils for Treatment of Medium and Large Sized (5mm or More) Intracranial Aneurysms: A Prospective Multicenter Study","PC400","Inclusion Criteria:\n\n* Subject is ≥ 18 and ≤ 80 years of age.\n* Subject has a previously untreated, ruptured or unruptured, saccular intracranial aneurysm 5mm or more in diameter for which the clinical decision to treat with Penumbra PC400 embolization coils has been made independent of the decision to enroll the subject in the study described in this protocol.\n* The decision to undergo the coiling procedure is made independently of and prior to participation in the research.\n* Subject has a baseline Hunt and Hess Score of I, II, or III.\n* Subject must be considered by the treating physician to be available for and able to complete all follow-up visits.\n* Subject has not been previously entered into this study.\n\nExclusion Criteria:\n\n* Subject is \\\u003C 18 or \\> 80 years of age.\n* Subject has a baseline Hunt and Hess score of IV or V.\n* Target aneurysm is dissecting, fusiform, blister-like, mycotic, tumoral, or AVM related.\n* Target aneurysm maximum diameter is \\\u003C5mm\n* Target aneurysm was previously treated via clipping or coiling.\n* Target aneurysm is deemed by the treating physician to be unsuitable for coiling or unlikely to be successfully treated by endovascular techniques.\n* Target aneurysm has not been confidently determined by the treating physician to be the source of SAH.\n* Planned use of a flow diverter (Surpass, Pipeline, Silk, FRED, p64, etc.) or intrasaccular device (WEB, Artis, Medina, etc.) as a component of the target aneurysm treatment plan.\n* Intended use of a coil-assist stent as a component of the target aneurysm treatment plan, unless stent is used for bailout purposes.\n* Subject has a known, untreatable hypersensitivity to contrast dye, iodine, hydrogel, or any other component of the treatment device.\n* Subject has a contraindication to heparin or aspirin.\n* Subject has vascular anatomy\u002Ftortuosity preventing access to the target aneurysm.\n* Subject is unable to undergo DSA or DSA is determined unsuitable or outside standard of care by the treating physician.\n* Subject has a serious or life-threatening comorbidity that could confound study results.\n* Subject is at high risk of noncompliance due to a history of substance abuse, psychosocial issues, etc.\n* Subject is unable to complete scheduled follow-up assessments due to comorbidities, geographical limitations, or a life expectancy of less than 18 months.\n* Subject is pregnant, breastfeeding, or plans to become pregnant prior to completion of follow-up.\n* Subject is enrolled in another device or drug study in which participation could confound study results.",{"count":180,"type":22},100,"18 Months","The goal of this prospective, observational study is to evaluate the long-term occlusion rates and safety of the Penumbra PC400 coil in the treatment of ruptured and unruptured intracranial aneurysms in adult subjects ages 18-80.\n\nSpecifically, the study aims to analyze rate of death, stroke, neurological death, or rebleeding associated with the treatment of intracranial aneurysm with the PC400 coil.\n\nParticipants will undergo standard of care treatment and follow up for their aneurysm treatment, and participating sites will collect procedural and follow up data.",[28,184],"Saccular Aneurysm",[186,187],"Intracranial aneurysm","Coiling","2026-03-09",{"date":160,"type":38},{"date":191,"type":22},"2026-05",{"date":193,"type":22},"2029-12",{"name":195,"class":45},"Semmes-Murphey Foundation",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":4},"100594653","evaluation-of-a-novel-intrasaccular-embolization-device-for-the-treatment-of-intracranial-aneurysms-100594653","NCT07022249","Evaluation of a Novel Intrasaccular Embolization Device for the Treatment of Intracranial Aneurysms","Efficacy and Safety of a Novel Intrasaccular Embolization Device for the Treatment of Intracranial Aneurysms : a Prospective, Multicenter, Single-arm Trial","Inclusion Criteria:\n\n* Patient must be 18-75 years of age at the time of screening.\n* Patient must have a single ruptured or unruptured IA requiring treatment.\n* Patient was able to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule, signed and dated an written informed consent prior to initiation of any study procedures.\n\nExclusion Criteria:\n\n* Patient had an IA with characteristics unsuitable for endovascular treatment.\n* Patient had vessel characteristics, tortuosity or morphology which precluded safe access and support during treatment with study device.\n* Patient had vascular disease or other vascular anomaly that precluded the necessary access to the aneurysm for use of the study device.\n* Patient had vasculitis, an intracranial tumor (except benign tumors that do not require treatment) or any other intracranial vascular malformations on presentation.\n* Patient was taking anticoagulants or had a known blood dyscrasia, coagulopathy, or hemoglobinopathy.\n* Patient was pregnant.",{"count":204,"type":22},150,[25],"The study is a prospective, multicenter single-arm cohort. The purpose of this study is to evaluate efficacy and safety of a novel intrasaccular embolization device for the treatment of intracranial aneurysms.",[28],"2025-06-08",{"date":210,"type":38},"2025-06-15",{"date":212,"type":22},"2025-06",{"date":214,"type":22},"2027-06",{"name":216,"class":169},"Ton-Bridge Medical Tech. Co., Ltd",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":46},"100588402","post-market-product-surveillance-of-intracranial-aneurysms-treated-with-commercial-registered-acandis-devices-in-france-100588402","NCT06940934","Post-Market Product Surveillance of Intracranial ANeurysms Treated With Commercial ReGistered ACANDIS Devices in FrancE","ANCRAGE: Post-Market Product Surveillance of Intracranial ANeurysms Treated With Commercial ReGistered ACANDIS Devices in FrancE","ANCRAGE PMS","Inclusion Criteria:\n\n* The subject has an intracranial aneurysm that can be treated with one of the Acandis device indicated for the treatment of intracranial aneurysms.\n* The subject is 18 years of age or older.\n* The subject is willing to comply with scheduled visits and examinations, per institution standard of care.\n\nExclusion Criteria:\n\n* The subject has provided tacit opposition to data collection.\n* Any IFU warning will be considered for exclusion in the cohort.",{"count":180,"type":22},"The aims of this clinical data collection are to investigate mortality, morbidity and neurological outcome 12 months after treatment of subject's intracranial aneurysm(s) and additionally to evaluate potential residual risks associated with the use of the commercial device(s) and to ensure the long-term safety and performance of Acandis Device(s) after its placing on the French market. On top of this, these cohorts will generate data for getting the renewal of the device's reimbursement on the French market.",[28],"2025-04-16",{"date":230,"type":38},"2025-04-23",{"date":232,"type":38},"2021-12-01",{"date":234,"type":22},"2027-04",{"name":236,"class":169},"Acandis GmbH",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100553459","phase-4-comparison-of-the-antiplatelet-efficacy-of-aspirin-combined-with-clopidogrel-and-aspirin-combined-with-half-dose-ticagrelor-in-patients-with-unruptured-intracranial-aneurysms-with-normal-cyp2c19-metabolizer-phenotype-100553459","NCT06486363","Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype","Inclusion Criteria:\n\n1. Patients with unruptured intracranial aneurysms who are scheduled for stent-assisted embolization;\n2. mRS score less than or equal to 2 on admission;\n3. Normal CYP2C19 metabolizer genotype;\n4. Age 20 or above, 70 or below, regardless of gender;\n5. The subject or the entrusted family member voluntarily signed the informed consent for this trial\n\nExclusion Criteria:\n\n1. Use of drugs that affect coagulation function or significant abnormalities in platelet\u002Fcoagulation function before admission;\n2. Previous history of cardiovascular and cerebrovascular disease;\n3. Complications of major organ dysfunction, chronic inflammatory diseases or malignant tumors at admission;\n4. Known allergy or contraindication to heparin, aspirin, clopidogrel, or ticagrelor;\n5. Patients with any severe or active pathological bleeding;\n6. Pregnant and lactating female;\n7. Those deemed unsuitable to participate in this trial by the responsible physician","20 Years","70 Years",{"count":21,"type":22},[247],"PHASE4","The goal of this clinical trial is to compare the antiplatelet efficacy of aspirin combined with clopidogrel and aspirin combined with half-dose ticagrelor in in patients with unruptured intracranial aneurysms with normal CYP2C19 metabolizer phenotype. The main questions it aims to answer are:\n\nIf aspirin combined with half-dose ticagrelor is comparable to or better than aspirin combined with clopidogrel? What medical problems do participants have when taking aspirin combined with half-dose ticagrelor? Researchers will compare aspirin combined with half-dose ticagrelor to aspirin combined with clopidogrel to see if aspirin combined with half-dose ticagrelor works to treat patients with unruptured intracranial aneurysms received endovascular treatment.\n\nParticipants will:\n\nTake aspirin combined with half-dose ticagrelor or aspirin combined with clopidogrel every day for 6 months Visit the clinic 1 month and 6 months for checkups and tests",[28,250],"Antiplatelet Drugs","2024-07-26",{"date":253,"type":38},"2024-07-29",{"date":255,"type":22},"2024-08-01",{"date":257,"type":22},"2027-07-31",{"name":259,"class":45},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"]